Meeting
2023 ASCO Annual Meeting
Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment.
Authors
Xiaochun Zhang
The Affiliated Hospital of Qingdao University, Qingdao, China
Xiaochun Zhang , Xingya Li , Minghong Bi , Chunxia Su , Yong Fang , Zibing WANG , Ying Yuan , Xiuping Du , Tangfeng Lv , Yingyin Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04890795
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8585)
DOI
10.1200/JCO.2023.41.16_suppl.8585
Abstract #
8585
Poster Bd #
212
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).
First Author: Wei Li
Poster
2024 ASCO Annual Meeting
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.
First Author: Chunjiao Wu
Poster
2023 ASCO Annual Meeting
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
First Author: Shubham Pant
Poster
2023 ASCO Annual Meeting
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
First Author: Nirav Niranjan Shah